Celcuity Sinks Amid Market Concerns, Stocks Drop

CELC Celcuity shares fell more than 20% in morning trading on June 2, 2026, despite the company posting strong Phase 3 data for gedatolisib in breast cancer at a major oncology conference. The VIKTORIA-1 trial showed the gedatolisib triplet reduced the risk of disease progression or death by 50% versus the alpelisib-plus-fulvestrant comparator arm (HR=0.50; 95% CI: 0.37-0.68; p<0.0001), with median progression-free survival of 11.1 months compared to 5.6 months for the control group. The FDA has set a PDUFA target decision date of July 17, 2026 for the drug candidate.

The market reaction appeared to reflect a classic "sell the news" dynamic: Celcuity shares had rallied significantly ahead of the data readout, and the detailed results, while clinically meaningful, may have prompted some investors to reassess the commercial opportunity or question the competitive landscape as PI3K-alpha inhibitor combinations face scrutiny on tolerability. The stock decline did not reflect any new clinical safety concerns; the trial data showed a favorable safety profile for the gedatolisib combination relative to existing alternatives.

Separately, SHAK Shake Shack also weighed on investor sentiment after cutting its Q2 2026 guidance . The company revised its Q2 same-shack sales growth projection to 2.5%-3.0%, down from the prior range of 3.0%-5.0%, and lowered its Q2 restaurant-level profit margin guidance to 22.0%-23.0% from 24.0%-24.5%. Full-year adjusted EBITDA guidance was trimmed to $225-$235 million versus the prior $230-$245 million range. Shake Shack shares fell approximately 7% on the day, with management citing macroeconomic uncertainty and increased competition as the primary drivers of the softer outlook.

Related Stocks

• CELC
• SHAK